Eli Lilly has agreed to buy AtaiBeckley for up to $3.8 billion, acquiring a promising psychedelic nasal spray drug, BPL-003, aimed at treating resistant depression. This deal highlights the growing acceptance of psychedelics in medicine, building on decades of British research. BPL-003 is currently in phase III trials, with early data showing significant patient improvement. Lilly’s upfront payment of $2.8 billion reflects confidence in psychedelics as a new approach to mental health treatment, despite the drug being years from market approval.
Atlas Healthcare Fund, managed by VST Capital, invested in Eli Lilly at around $350 per share in 2020, well before its GLP-1 drug tirzepatide became a major success. The stock now trades above $1,200, reflecting a gain of over 246%. This early invest...
The active healthcare ETF TMED has surged 18.6% year-to-date, outperforming its benchmark and category average. Its top holding, Eli Lilly, has benefited from rising demand for weight loss drugs, boosting the fund's performance. TMED uses active mana...
Health stocks Eli Lilly (LLY), United Health Group (UNH), and Merck (MRK) have recently seen positive developments, including drug approvals and strong earnings. These gains have boosted their stock prices, with LLY up over 8% YTD, UNH up 25.8% YTD, ...
Kalshi, an online gambling platform, has introduced new betting markets where users can wager on the results of late-stage pharmaceutical clinical trials and FDA drug approval decisions. The markets focus on Phase 3 trials from large biopharma compan...
Eli Lilly has agreed to acquire clinical-stage biotech AtaiBeckley in a deal valued at up to $3.8 billion, adding promising therapies for treatment-resistant depression to its neuroscience portfolio. Lilly will pay $6.75 per share upfront, with addit...
